Although East Asians make up a significant share of entry-level roles in U.S. biopharma, few have risen to senior leadership positions. That disparity is what inspired the launch of ElevAAte—a new nonprofit founded this year to support and grow East Asian American leadership in the industry. In this week’s episode of "The Top Line," Fierce Pharma D…

We’ve known for a while that there are two Anguses—both journalists covering oncology at health- and biopharma-focused news outlets. Now, for the first time, we’re bringing them together for a “Variety Studio: Actors on Actors”-style conversation. In this week’s episode of "The Top Line," Fierce Pharma Deputy Editor Angus Liu and STAT Cancer Report…

After a batch of much-anticipated reciprocal tariffs spared pharmaceuticals in early April, drugmakers, medtech companies, manufacturers and other outfits across the life sciences spectrum are still scrambling to respond to mounting trade pressures. While many unknowns remain, biopharma companies should waste no time in starting to evaluate their o…

In this week’s episode of "The Top Line," Fierce Deputy Editor Andrea Park and Fierce Biotech Senior Editor Gabrielle Masson discuss how workforce reductions impacted the biopharma industry in the first quarter. The pair examine industry trends, company closures, developments in the cell and gene space—and the reductions in force happening at feder…

In this week’s episode of "The Top Line," Fierce Biotech’s Gabrielle Masson and Darren Incorvaia sit down to discuss a recent special report from Fierce Biotech, ranking the top 10 R&D budgets from 2024. Did Merck hold on to its 2023 crown? And did any new faces crack this year’s list? Listen to find out! To learn more about the topics in this epis…

Since the first days of the new Trump administration, the White House has handed down orders to ban work focused on diversity, equity and inclusion (DEI) across the federal government. Some in the private sector—both inside and outside of healthcare—have followed the same path, eliminating DEI officer positions and ending initiatives that in some c…

In this episode of The Top Line, sponsored by PatientPoint, Andrew Schultz, President of PatientPoint Precision, discusses how hypertargeting and contextual relevance are redefining patient marketing. Traditional direct-to-consumer (DTC) campaigns often rely on educated guesses, but PatientPoint Precision blends EHR data and patient context to deli…

Johnson & Johnson’s Stelara, Regeneron’s Eylea and Amgen’s Prolia are just some of the drugs facing off against new biosimilars or generics in 2025, as featured in the latest edition of Fierce Pharma’s annual special report documenting the 10 biggest losses of U.S. exclusivity expected throughout the year. In this week’s episode of The Top Line, we…

Agenus Chief Medical Officer Dr. Steven O'Day joined Fierce's Chris Hayden on a recent sponsored episode of The Top Line podcast to discuss the evolving landscape of cancer immunotherapy. O'Day, a medical oncologist with 30 years of experience, explained the fundamental differences between immunotherapy and traditional cancer treatments like chemot…

Despite a rocky start for many drugmakers at the start of last year, 2024’s fourth quarter saw just two of the top 25 global pharma companies record sales declines. But that growth may be short-lived, as many of those same companies forecast more muted revenue increases in 2025. In this week’s episode of The Top Line, we dissect the unprecedented r…

In the latest episode of The Top Line, Chris Hayden of Fierce Pharma sits down with Mary Lou Glotzbach, senior manager of drug delivery partnerships at Grand River Aseptic Manufacturing (GRAM). They explore the evolving landscape of biologics, the increasing importance of cold chain management, and how contract development and manufacturing organiz…

The latest episode of The Top Line, sponsored by ViiV Healthcare, features Dr. Luis Buzón, an infectious disease specialist, discussing the critical role of real-world evidence in HIV treatment and prevention. While clinical trials establish the safety and efficacy of new therapies, real-world data help bridge the gap between these highly controlle…

For the biotech industry, 2024 meant the return of the venture capital megaround. And one startup, Xaira Therapeutics, took it a step further, expanding the industry’s definition of a megaround by reeling in a rarely seen $1 billion financing early in the year. In this week’s episode of The Top Line, we dive into a recently published report from Fi…

Huntington’s disease was long thought to be caused by the slow buildup of a toxic protein, but new research has revealed that it’s actually driven by the expansion of a gene that, at a certain length, triggers quick neuron death. In this week’s episode of The Top Line, we hear from Steven McCarroll, Ph.D., a Huntington’s disease researcher at the B…

Clinical-stage drug development offers big rewards—and big risks. To that end, Fierce Biotech recently published its annual roundup of several of the most eye-catching trial failures of the preceding year. The 2024 list includes trial flops from the likes of AbbVie, Novo Nordisk, Pfizer and more, with reports of disappointing results in many tough-…

Valentine’s Day represents a perfect opportunity to highlight news and updates from across biopharma that have hearts all aflutter. In this week’s episode of “The Top Line,” we do just that, fueled by heart puns and holiday candy. Fierce’s Gabrielle Masson and Andrea Park discuss a new heart-focused biotech that recently emerged with $300 million a…

If Fierce Pharma Marketing’s annual list of the top 10 biggest potential drug launches of the coming year is any indication, biopharma may soon be in for a blockbuster boom. All together, the 10 meds that made the 2025 list stand to generate a whopping $29 billion in annual sales by the end of the decade. In this week’s episode of The Top Line, we …

During a panel discussion at this year’s Fierce JPM Week—which took place alongside the annual J.P. Morgan Healthcare Conference in San Francisco—industry experts broke down what it takes to pull off a successful biotech IPO in the current market. This week’s episode of The Top Line dives into the discussion, featuring Fierce Biotech’s Gabrielle Ma…

This year’s edition of the annual J.P. Morgan Healthcare Conference has come to a close, with attendees enjoying sunny skies and a heavy police presence throughout the San Francisco-set event. In this week’s episode of The Top Line, Fierce Pharma’s Zoey Becker and Angus Liu join Fierce Biotech’s Darren Incorvaia to break down the biggest news stori…

Following the strange year for the biopharma industry that was 2024, insiders and analysts alike are waiting expectantly to see how trends in layoffs, drug shortages, clinical trials and more play out in 2025. Meanwhile, a second Trump term and a spree of related health agency nominations raise serious questions about how health policy could shift …

Arun Krishna, Vice President and franchise head for an AstraZeneca US OBU, shares details of a treatment option with TAGRISSO® (osimertinib). AstraZeneca is focused on the development of new treatments, prioritizing researching options in eligible patients. Listen to the full podcast episode to learn more. Please see Important Safety Information fo…

A review of the FDA’s drug approvals of 2024 shows that small companies loomed large—both in the sheer number of nods gained and the significance of the new drugs and biologics that these firms are bringing to the market. In this week’s episode of “The Top Line,” we take a deep dive into the FDA’s list of drugs that were approved in 2024. Fierce Ph…

In this week’s episode of "The Top Line," we bring you a special conversation from earlier this month at our New York City gala, where we celebrated this year’s Fierce 50 honorees. On stage, five extraordinary leaders shared their insights, experiences, and bold ideas shaping the future of healthcare and beyond. These honorees represent the five ca…

GLP-1 agonists have taken the pharma world by storm, and Novo Nordisk has been at the forefront of it all with its blockbuster drug semaglutide, which it sells as Ozempic, Wegovy and Rybelsus. Semaglutide and other GLP-1s have gained widespread popularity as treatments for Type 2 diabetes and obesity, and it doesn’t stop there—they’re currently bei…

(This podcast was recorded on June 7th, 2023) Kyle Chaboya is one of my best friends. He's among the most inspiring, motivational, and persistent people I have ever met. In this episode, Kyle and I (Caleb Hodgson) chop it up about how our relationship started in 6th grade and continues today. We chatted about the challenges of growing up with Cereb…

The boys recap ALL the crazy from the past weekend of College Football, nothing else, and no notes.By The Fiends Podcast Network

After a promising start to the year, the biotech IPO market picked up steam again late this summer, with notable offerings from companies like Upstream, Septerna and BioAge. But what does this mean for the sector? Is market enthusiasm truly returning, or are we just seeing a temporary rebound? To unpack these questions and look ahead to 2025, Fierc…

Format Ugly morning window, great witching hour. Texans lose to Mayo Boy. Stroud Boys in trouble? Bryce Young has a pulse, as the Chiefs survive another close game. Are the commanders possibly getting exposed? Patriots race to the bottom? Brett gives a very short reaction to the game. Discuss what Maye could use at the top of the draft. The Niners …

Every year, Fierce’s pharma, biotech, and medtech teams come together to spotlight some of the fiercest women in life sciences—leaders who are transforming the industry with their innovation and impact. This year, our special report celebrates 10 women driving change in clinical research, business development, venture capital, and beyond. In this w…

The Fiends are back from a two-week hiatus with a special in-person recording session for the first time in show history. Brett gives us insight into the environment he experienced in Corvallis last weekend, where the Spartans took down Oregon State in one of the biggest wins in program history. Hunter is not worried about the Niners as they win in…

 Last month, the NIH announced that it had found evidence of research misconduct by Eliezer Masliah, M.D., the head of the neuroscience division at the National Institute on Aging. The NIH announcement coincided with the Sept. 26 publication of an investigation by Science, finding that 132 papers published by Masliah appear to contain manipulated i…

Each year, we dive into the world of biotech closures and layoffs, tracking the industry’s pulse as companies navigate high risks and harsh realities. In this week's episode of "The Top Line," Fierce editors Gabrielle Masson and Andrea Park take a closer look at this year’s biotech graveyard, which tracks biotechs that have shuttered or are in the …

As the 2024 U.S. presidential election nears, the choice between Democratic nominee Vice President Kamala Harris and Republican nominee former President Donald Trump will shape the future of drug pricing policy. While both candidates have pledged to reduce drug costs, their approaches are likely to differ significantly. In this week's episode of "T…

Caleb is so tired after pilates, it’s got him feeling like Anthony Richardson. The Jets are the worst team in America. Brett breaks down the Pat's defensive performance and the impact of Drake Maye's Injury. Caleb takes a mental health day, as the Raiders fall to the rival Chiefs. The boys discuss their half-baked MVP, Super Bowl, and bold predicti…

Discover how Turbine Simulated Cell Technologies is transforming drug development by addressing biases in training data. Guests Bence Szalai, MD, PhD, and Istvan Taisz, MD, PhD, share insights on the challenges of biased AI models in biology and introduce their groundbreaking framework, EFFECT (Evaluation Framework for Predicting Efficacy of Cancer…

EY recently published their 18th annual Pulse of the MedTech Industry report, highlighting how—despite steadily rising profits year-over-year—devicemakers large and small are still being squeezed by the cost of doing business and waning investor enthusiasm. During AdvaMed’s MedTech Conference this month in Toronto, John Babbitt, partner on the life…

The boys start the pod by sharing sports trauma, and reminding Brett how great his sports life has been. Hunter is not worried about the Niners, but Kyle and Purdy are under fire after a pathetic performance against the Chiefs. It's the Bugatti Drake Maye Daye in London!!! The boys discuss Mayo’s postgame comments after a tough loss. Bill throwing …

At this year’s Fierce Biotech Summit in Boston, we caught up with leaders in the biotech industry who have been recognized as past Fierce 15 honorees. These private biotechs have made significant contributions to their field, and their groundbreaking work is shaping the industry's future. Fierce Biotech’s Gabrielle Masson sat down with Liang Schwei…

The Fiends get into the news of the day with Caleb giving his take on Tae Adams to the Jets and Brett's analysis on Amari Cooper's fit in the Bills offense. Raiders are cooked, but the introduction of Brady into the ownership group may bring hope to Caleb and Raiders fans everywhere. If we can get him out of the announcer's booth and in charge of t…

In this episode, we dive into the world of gene therapy logistics with Cryoport Systems' innovative Elite Ultra Cold shipping system. Mike Dybicz and Khoa Tran are in the hotseat to discuss how their solution addresses critical challenges in transporting temperature-sensitive gene therapies. The pair explain how Cryoport Elite offers extended hold …

The neuroscience sector has seen a surge in investment over the past year, leading to breakthroughs and high-stakes deals, especially in the closing months of 2023. This momentum shows no signs of slowing, as companies continue to push boundaries in neuroscience and psychiatric disease research. At this year's Fierce Biotech Summit on Oct. 1, pharm…

The Fiends jump straight into the news of the day with a discussion about Robert Saleh getting fired by the Jets (0:16 - 14:38). Brett’s expectations as Drake Maye gets the start in week six against the Texans (14:39- 29:17). Up next for the boys is a deep dive into the 49er's struggles on both ends and what Hunter's expectations for the rest of th…

Since the introduction of the BIOSECURE Act in January, named companies and U.S.-based biopharmas alike have speculated on what the legislation could mean for the life sciences industry. In this week's episode of "The Top Line," Fierce Pharma staff writer Fraiser Kansteiner sits down with Arnold & Porter’s Life Sciences practice chair Dan Kracov to…

Caleb hates “sources”, as the boys explore the Tuesday drama linked to the supposed Devante Adams trade request (0.00-11:50). Raiders take down Massage Watson, With Caleb and Brett breaking down the scrappy Raiders defense, along with the rising star Brock Bowers. (11:57-27:30). We have a Pod faceoff on our hands!!! Brett tells the hard truth about…

At the recent World Conference on Lung Cancer and European Society for Medical Oncology annual meetings, two packages of lung cancer data from a partnership between Akeso and Summit Therapeutics and another collaboration between iTeos Therapeutics and GSK showed much promise of disrupting the current standard of care. But they also drew some questi…

Segments "Film Talk" with Brett Pats Jets (TNF ) Positives/Worries Maye garbage time reps? Outlook for the rest of the season @ 49ers next week Niners Rams (Injury Bowl) QB Show Positives/worries Outlook for 49ers rest of season Mcvay/Shanny Raiders Panthers Fluke or panic time in LV? APs comments Positives/worries Outlook for Raiders rest of seaso…

Show Script Raidas upset the Ravens Mad Max = Game Wrecker Who’s laughing at Bowers's pick now? Road to Success looking ahead? Gardner's stats look good lol Niners vs Vikings: The Flores Game Injuries haunting? Did Flores outcoach Shanny?- Fred Warner becoming an all-time great ILB What is it about Kyle's drop-back game that has experts questioning…

In this week's episode of "The Top Line," we’re recapping and discussing the major trends from Digitial Pharma East, which took place in Philadelphia last week. The event brought together marketing experts from across the life sciences industry. Fierce Pharma Marketing's Andrea Park and Ben Adams talk about major trends from the event that came up …

In this week's episode of "The Top Line," we will dive into the annual Fierce 50 special report. We share the stories of a select few 2024 Fierce 50 honorees and interesting highlights from this year's special report. To learn more about the topics in this episode: Fierce 50 of 2024 Innovation Honorees Health Equity Honorees Social Impact Honorees …

Segments - MNF: 49ers dominate the Goddamn Jets - Manning cast with Bill - Pats upset the Bengals - Raiders lose to the Chargers - NFL Redzone recap - SJSU vs Air Force - Oregon vs Boise St - Colorado Clickbait - Bama vs USFBy Eclection Podcasts